Project Grant HT94252510739
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01605, USA
Similar Awards
- The Department of Defense's Defense Health Agency awarded a $1,330,054 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of California, San Francisco (UCSF). The grant supports the "CLINICAL VALIDATION AND IMPLEMENTATION OF A HOST-PATHOGEN-BASED DIAGNOSTIC ASSAY FOR EARLY LYME DISEASE AND OTHER TICK-BORNE INFECTIONS" project, with a performance period from July 1, 2024 to June 30, 2027. As a leading academic medical...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $542,500 Project Grant to Worcester Polytechnic Institute (WPI) to develop a novel human in vitro genome-wide association platform to study the pathogenesis of Borrelia burgdorferi and genetic susceptibility to Lyme disease. The grant, which runs from July 1, 2025 to June 30, 2028, will support advanced biomedical research aimed at transforming healthcare for military service...
- The Defense Health Agency awarded Duke University a $1,255,621 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop diagnostic and therapeutic agents targeting Borrelia burgdorferi, the causative agent of Lyme disease. The grant, with a performance period from September 15, 2024 to September 14, 2027, will enable Duke to conduct innovative biomedical research aimed at improving health outcomes for military service members and the broader public. As a...
- This federal Project Grant award of $1,176,645.00, granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a highly accurate proteomic diagnostic assay to identify active Borreliosis (Lyme disease) infection with point-of-need collection technology. The grant recipient, George Mason University, will conduct this research in collaboration with a subcontract to The Johns Hopkins University, which will provide...
- Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...
- This $870,886 federal Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a subunit vaccine against Babesiosis caused by Babesia microti at Tufts Medical Center Parent, Inc., a non-profit academic medical center in Boston, MA. The 3-year award, which began on September 1, 2023, will fund research efforts to create a new vaccine to prevent this tick-borne illness that can affect military...
- The Defense Health Agency awarded a $456,633 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. The grant funds the development and optimization of a platform for next-generation monoclonal antibodies against Powassan virus and other neuroinvasive tick-borne viruses. Key collaborators include researchers from the United States Army Medical Research Institute of Infectious...
- The Department of the Army Medical Command awarded a $449,402 Project Grant to Texas A&M University System Health Science Center through the Military Medical Research and Development program. The grant will fund research from September 2021 to August 2023 to investigate the role of the adenylate cyclase CyAB and the cyclic AMP signaling pathway at the Borrelia burgdorferi host-pathogen interface. The Military Medical Research and Development program aims to advance biomedical research that...
- The U.S. Defense Health Agency awarded Microquin LTD a $798,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize MIC compounds for the treatment of renal cell carcinomas. The award period runs from November 1, 2025 to April 30, 2027. Microquin LTD, a biotechnology company based in Cambridge, Massachusetts, specializes in advanced medical research and the development of innovative therapeutic solutions, particularly in the areas of gene therapies...
- This federal Project Grant award of $1,292,721.00, awarded on September 30, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the University of Maryland, College Park in developing novel small-molecule therapeutics against Lyme disease. The award has an ultimate completion date of September 29, 2028. As a research-intensive university, the University of Maryland, College Park has extensive expertise in conducting advanced...